Georges Gemayel

Georges Gemayel currently works at GlycoEra AG, as Chairman from 2022, Supernus Pharmaceuticals, Inc., as Independent Director from 2015, International Institute of New England, as Director, Flamingo Therapeutics BV, as Director, St Andrews School In Ngong, Inc., as Director, Disc Medicine, Inc., as Director from 2022, Gemayel Investment LLC, as Partner from 2012, and Gemayel Family Foundation, as Trustee.
Dr. Gemayel also formerly worked at Altus Pharmaceuticals, Inc., as Chairman, President & Chief Executive Officer from 2008 to 2009, Gemini Therapeutics, Inc., as Executive Chairman, President & CEO in 2022, FoldRx Pharmaceuticals LLC, as Executive Chairman, OxThera AB, as Chairman, Syndexa Pharmaceuticals Corp., as Executive Chairman from 2011 to 2012, EpiTherapeutics ApS, as Chairman, Syndex Corp., as Executive Chairman, Strategic Partners A, as Chairman from 2014 to 2022, Vascular Magnetics, Inc., as Executive Chairman, EpiTherapeutics ApS, as Chairman, Dynacure SA, as Chairman, NPS Pharmaceuticals, Inc., as Director in 2012, Adolor Corp., as Independent Director in 2011, Momenta Pharmaceuticals, Inc., as Independent Director from 2016 to 2020, Prosensa Holding NV, as Director, Horizon Pharmaceutical LLC, as Independent Director from 2015 to 2016, Raptor Pharmaceuticals, Inc., as Director, Dimension Therapeutics, Inc., as Independent Director from 2015 to 2017, Enterome SA, as Non-Executive Director, Genzyme Corp., as Executive Vice President-Therapeutics from 2003 to 2008, Hoffmann-La Roche, Inc., as Vice President-National Specialty Care from 2000 to 2003, Hoffmann-La Roche Portugal, as General Manager from 1998 to 2000, Roche Farmacêutica Química Lda., as General Manager, and Roche Corp., as Vice President-National Specialty Care.
Dr. Gemayel received his graduate degree and doctorate degree from Université de Paris XI Paris Sud and doctorate degree from St. Joseph University.